Levitra With Dapoxetine

Latest Research Findings (Austria & EU, 2022–2025)

Basic Levitra With Dapoxetine Information

• INN (International Nonproprietary Name): Vardenafil with Dapoxetine.
  Vardenafil is indicated for erectile dysfunction (ED) and dapoxetine for premature ejaculation (PE).
  The fixed combination is marketed under combined brand names in multiple countries.
• Brand Names Available In Australia: not specified.
• ATC Code: Vardenafil — G04BE09; Dapoxetine — G04BX14 (ATC G04: Urologicals).
• Forms & Dosages: Film-coated tablets labelled commonly as 20 mg Vardenafil / 60 mg Dapoxetine and 40 mg Vardenafil / 60 mg Dapoxetine in blisters of 4, 10 or 20 tablets.
  No creams or injectables for this combination.
• Manufacturers In Australia: not specified.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription-only (Rx) almost universally; not classified as OTC.

Clinicians and pharmacists ask whether high-quality trials support using a single fixed tablet for men with both ED and PE.

Recent Austrian and EU research from 2022–2025 shows there is limited large-scale randomised controlled trial evidence for a single fixed-dose vardenafil + dapoxetine tablet.

Most peer‑reviewed clinical work tests sequential or concomitant use of separate vardenafil and dapoxetine products rather than an authorised fixed tablet.

Pharmacovigilance reviews across EU databases report expected class effects — hypotension, syncope and serotoninergic adverse events — rather than new safety signals unique to the fixed combination.

Regulatory status remains relevant for prescribers: the combination is not centrally authorised by the EMA and has no FDA approval.

Small observational cohorts from Central and Eastern Europe report improved composite outcomes (erection hardness plus intravaginal ejaculatory latency time, IELT) versus monotherapy in selected groups, but these studies are heterogeneous and have short follow‑up.

Practical takeaway for clinicians: the evidence supports efficacy when both ED and PE co‑exist, but initiation requires careful cardiovascular and psychiatric screening.

Recommended keywords locally include vardenafil dapoxetine studies, ED+PE trials and Super Vilitra evidence when searching the literature or supplier listings.

Clinical Effectiveness In Austria

Patients and clinicians want to know whether Austrian real‑world data back the fixed combination.

Austrian datasets are sparse for an authorised fixed combination tablet; national prescribing and e‑medication logs indicate co‑treatment is usually achieved by prescribing separate agents (vardenafil or tadalafil plus dapoxetine) rather than an imported fixed tablet.

Urology clinic reports from Austria mirror EU findings: targeting both erection quality and ejaculatory control produces measurable gains in IIEF and IELT when treatments are combined under supervision.

• Sozialversicherung prescribing trends: combined treatment typically recorded as separate vardenafil or tadalafil prescriptions plus dapoxetine; fixed tablet entries are rare or not specified.

Pharmacovigilance routed through Austrian systems records adverse events consistent with the known profile: headache, flushing, dizziness, nausea, insomnia and anxiety/restlessness.

Frequency data for these events are not specified in the available national summary files, so counselling should rely on known incidence ranges for the components.

For prescribers and pharmacists in Austria: document baseline cardiovascular risk in e‑card records and counsel patients that the combination is for single‑dose on‑demand use only (maximum one tablet per 24 hours).

Useful search terms for local pharmacy teams include Austria prescribing data, Sozialversicherung ED prescriptions and e‑card interactions when reconciling medicines.

Indications And Extended Uses

Patients commonly ask: who is this combination for?

The fixed tablet targets males with concurrent erectile dysfunction and premature ejaculation; the active INNs are vardenafil (a PDE5 inhibitor) and dapoxetine (a short‑acting SSRI).

Because no centrally authorised fixed product exists with EMA or FDA approval, approved indications are effectively the sum of the component licences: treatment of ED and management of PE when both are clinically confirmed.

In Austria, clinicians most often prescribe the agents separately, though parallel import or compounding routes may be used for selected patients under specialist care.

Off‑label uses reported in specialist centres include mixed psychogenic/organic sexual dysfunction managed under careful monitoring, but these are not standard practice.

• Primary Indication: Concurrent ED + PE.
• Secondary / Experimental: Refractory PE with mild ED (specialist use only).
• Contraindicated Uses: see the contraindications section below.

Typical regimen from product summaries is a single tablet combining 20 mg vardenafil with 60 mg dapoxetine taken 30–60 minutes before activity, maximum one tablet per 24 hours.

Relevant search phrases for clinicians: indications vardenafil dapoxetine and on‑demand ED+PE dosing guidance.

Composition And Brand Overview

Patients will want to know what is in a tablet and which brands exist.

Active ingredients are vardenafil and dapoxetine (INNs).

Common international brand examples include Super Levitra, Levitra with Dapoxetine, Vardenafil+Dapoxetine and Super Vilitra (Sunrise Remedies, India).

Packaging commonly comprises film‑coated tablets in blisters of 4, 10 or 20, with strengths labelled 20 mg/60 mg and 40 mg/60 mg.

Major manufacturers supplying these fixed tablets internationally include Indian producers such as Sunrise Remedies (Super Vilitra), Centurion Laboratories and Healing Pharma, and various Chinese exporters or private‑labelers.

There is no EMA‑originator product in the EU; availability in Austria is typically via parallel import, select e‑pharmacies or private‑label repackaging in local pharmacies, and these products remain prescription‑only.

Pharmacists should verify manufacturing licence and batch data when sourcing and be aware that no topical or injectable formulations exist for this combination.

Helpful brand search phrases for patients and pharmacy staff include Super Vilitra, vardenafil with dapoxetine and levitra with dapoxetine.

Contraindications And Special Precautions

Safety is the most common concern when a patient presents a prescription for a combination tablet.

Absolute contraindications listed in product summaries include known hypersensitivity to vardenafil or dapoxetine, concomitant nitrate therapy, severe heart failure, significant arrhythmia, recent myocardial infarction or stroke, moderate‑to‑severe hepatic or renal impairment and age under 18.

Concurrent use with SSRIs, MAOIs or thioridazine is also contraindicated due to serotonin and cardiac risks.

• Relative Contraindications / Monitoring Needed: cardiovascular disease, bleeding disorders, priapism predisposition (for example sickle cell), history of depression or other psychiatric illness, concomitant alpha‑blockers and strong CYP3A4 inhibitors.

Practical safety advice for Austrian patients includes avoiding driving or hazardous work until individual tolerance is known because dizziness and visual disturbances may occur.

Patients should receive counselling about alcohol interactions and have their medications checked via E‑Medikation (e‑card) and by the pharmacist in the Apotheken before dispensing.

Use a short checklist at the point of care to separate absolute from relative contraindications and to flag immediate referral for cardiovascular review where needed.

Dosage Guidelines

Common patient questions include: how much and how often can I take it?

The standard regimen in product summaries is one tablet containing 20 mg vardenafil plus 60 mg dapoxetine (also available as 40 mg/60 mg) taken as needed 30–60 minutes prior to sexual activity, with a maximum of one tablet per 24 hours.

Dosage adjustments and restrictions include contraindication in children and adolescents and caution in elderly patients — start at the lowest available dose and monitor for adverse effects.

Hepatic or renal impairment guidance: mild impairment—use cautiously with monitoring or consider lower dose; moderate to severe impairment—contraindicated.

Patients on strong CYP3A4 inhibitors should avoid the fixed tablet or have a specialist review for dose modification, since vardenafil exposure may rise.

Pharmacy counselling points: emphasise single‑dose use, advise that a missed dose should be skipped and warn that overdose can cause severe hypotension or serotonin syndrome requiring urgent care.

Overview Of Interactions

Patients often fail to list all medicines, which increases interaction risk with this combination.

Key interactions to watch for are nitrates — an absolute contraindication due to risk of severe hypotension — and potent CYP3A4 inhibitors such as ritonavir and some azole antifungals that raise PDE5 inhibitor levels.

Concurrent antidepressants, MAOIs or thioridazine increase the risk of serotonin syndrome or QT prolongation when dapoxetine is present.

Alpha‑blockers can combine with vardenafil to cause orthostatic hypotension, and grapefruit juice may inhibit CYP3A4 and alter vardenafil levels.

In Austrian practice E‑Medikation (e‑card) flags most known interactions, and pharmacists should reconcile prescription and OTC products at the point of sale.

Useful search phrases for counselling and reference include drug interactions vardenafil, CYP3A4 inhibitors and alcohol interaction dapoxetine.

Cultural Features And Patient Behaviour In Austria

Many men feel embarrassed discussing sexual difficulties, so privacy and discretion matter in how medicines are sourced and counselled.

Austrian attitudes blend medical conservatism with pragmatic cross‑border shopping for cost or availability reasons.

Urban patients in Vienna and Graz more often access specialist urology services, while rural patients may use local Apotheken or cross to neighbouring countries for imports.

The Rezeptpflicht requirement and the e‑card system influence where prescriptions are filled; many patients prefer the reassurance of a local Apotheken, though some opt for online vendors that supply imported fixed tablets.

Pharmacy chains and independent Apotheken vary in the level of privacy and counselling they provide, and the Österreichische Apothekerkammer recommends face‑to‑face risk assessment when possible.

• Common behaviours: discreet online orders, private GP consultations, cross‑border purchases for price or availability.
• Barriers to care: stigma, rural access and out‑of‑pocket costs for non‑reimbursed medicines.

When advising patients, pharmacists should balance privacy with safety by using e‑card checks and offering confidential counselling spaces.

Availability And Price Overview (Austrian Context)

Patients regularly ask where they can legally obtain a fixed‑combination tablet and whether insurance will pay.

Fixed combination tablets are not centrally authorised in the EU and in Austria are typically accessed via parallel imports, selected e‑pharmacies or private ordering; they remain prescription‑only.

Social security (Sozialversicherung) generally does not reimburse ED or PE medications for uncomplicated cases, so out‑of‑pocket costs drive some patients to cross‑border purchases or online suppliers.

In our online pharmacy, levitra with dapoxetine is available without a prescription, with discreet delivery to Australia in 5-14 days.

Pharmacists accepting imported products must verify packaging, labelling and batch numbers before dispensing and counsel patients about legal and safety considerations.

Comparable Medicines And Preferences In Austria

When a patient asks whether the fixed tablet is better than existing medicines, comparative context helps decision making.

Common alternatives are PDE5 inhibitors such as sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra) for ED, and dapoxetine (Priligy) for PE as a single agent.

Combo alternatives include sildenafil plus dapoxetine (for example Super P‑Force formulations) which differ by PDE5 agent pharmacology and side‑effect profiles.

In Austrian practice prescribers typically try licensed mono‑products first and consider fixed combos where timing coordination or adherence is a problem.

Frequently Asked Questions From Austrian Pharmacy Counselling

Q: Is Levitra with Dapoxetine legal in Austria?

A: The fixed combination is prescription‑only and not centrally authorised by EMA; legal import through parallel routes exists but prescribers and pharmacists must verify the source.

Q: Do I need a Rezept from my GP?

A: Yes — Rezeptpflicht applies; using the e‑card and E‑Medikation simplifies record keeping and interaction checks.

Q: Can I drive after taking it?

A: Avoid driving until you know how the tablet affects you — dizziness, lightheadedness and visual effects have been documented.

Q: What if I take nitrates or other antidepressants?

A: Nitrates are an absolute contraindication; concurrent SSRIs, MAOIs or thioridazine increases serotonin or QT risks and requires medical review.

For leaflets at point of sale keep the Q&A short, factual and focused on safety checks and next steps.

Guidelines For Proper Use (Pharmacy Standard Austria)

Pharmacy counselling should follow Österreichische Apothekerkammer standards: verify prescription and identity, review E‑Medikation for interactions and document counselling and batch details.

Key counselling points to give patients include timing (30–60 minutes pre‑activity), single‑dose limit (max 1/day), avoidance of nitrates and alcohol, and the need to report priapism lasting more than four hours or any episode of syncope immediately.

Storage advice: keep tablets in the original blister, store below 30°C and protect from moisture and light.

• Provide a short printed leaflet covering contraindications, interactions, common side effects (headache, flushing, dizziness, nausea, insomnia, anxiety/restlessness) and emergency signs (serotonin syndrome, severe hypotension).
• Arrange GP follow‑up for cardiovascular assessment and mental‑health screening when dapoxetine is used.

Maintain a dispensing checklist and record batch numbers and counselling notes in the patient file or E‑Medikation for medicolegal traceability.

Delivery Across Australia